Investigations
Arons & Arons, LLC Announces Investigation on Behalf of WageWorks, Inc. Investors
March 01, 2018
The Law Firm of Arons & Arons, LLC has initiated an investigation of WageWorks, Inc. (NYSE : WAGE) (“WageWorks”) on behalf of the company’s shareholders for possible violations of federal securities law.
WageWorks investors who would like to discuss this investigation and their legal options should contact Arons & Arons, LLC (Jeffrey S. Arons, Esq.) at (973) 762-0795, (877) 512-7667 or email us at info@aronslaw.net.
WageWorks, Inc. announced today that it is delaying its Annual Report on Form 10K for the year ended December 31st, 2017 and its financial results and associated conference call for the fourth quarter of 2017. Following this release, the Company’s stock dropped to $10.25 (20%) in afternoon trading.
If you are an investor in WageWorks or have information pertaining to this investigation, you are encouraged to contact Jeffrey Arons, Esq. (973) 762-0795, (877) 512-7667 or email us at info@aronslaw.net. For updates and information please visit https://www.aronslaw.net/investigations.
Arons & Arons, LLC. Announces an Investigation on Behalf of Advance Auto Parts, Inc. Investors
January 05, 2018
On August 15, 2017, Advance Auto reported disappointing second quarter fiscal 2017 financial and operational results and disclosed that “[c]omparable store sales for the quarter were flat.” Additionally, Advance Auto reduced its financial and operational guidance for fiscal 2017. Following this news, shares of the company’s stock declined $22.24 per share, or over 20.3%, to close on August 15, 2017 at $87.08 per share.
"Why Advance Auto Parts Shares are Spiraling 22% Lower"
If you are an investor in Advance Auto or have information pertaining to this investigation, you are encouraged to contact Arons & Arons, LLC (Jeffrey Arons, Esq.) at (973) 762-0795, (877) 512-7667 or email us at info@aronslaw.net. Please complete our online case information form to help our team better assess your case.
Arons & Arons, LLC. announces investigation on behalf of Eagle Bancorp Investors
December 06, 2017
According to a report issued by Aurelius Value, there was evidence of an insider loan scheme involving Eagle Bancorp Chairman and CEO Ronald D. Paul and other board members. The report references two undisclosed fraud suits filed by the founders of two businesses co-owned by Paul, where it is alleged that Mr. Paul used Eagle to issue large preferential loans in exchange for being personally awarded cheap equity stakes in Eagle borrowers. The article accuses Eagle of expanding into riskier Acquisition Development and Construction loans simply to fuel Mr. Paul’s own business interests rather than those of the shareholders. Following this news, shares of Eagle Bancorp fell over 24% from its previous closing price to close at $49.95 per share on December 1st, 2017.
If you are an investor in Eagle Bancorp, Inc. or have information pertaining to this investigation, you are encouraged to contact Arons & Arons, LLC. (Jeffrey Arons, Esq.) at (973) 762-0795, (877) 512-7667 or email us at info@aronslaw.net. Please feel free to click below to provide your holding information so we can assess your eligibility to serve as a lead plaintiff if a class action is ultimately filed.
Arons & Arons, LLC. announces investigation on behalf of Intercept Pharmaceuticals Inc. investors
September 22, 2017
The Law Firm of Arons & Arons, LLC. has initiated an investigation of Intercept Pharmaceuticals Inc. investors (“Intercept or the “Company”) (NASDAQ:ICPT) on behalf of the company’s investors for possible violations of federal securities law.
The Law Firm of Arons & Arons, LLC. has initiated an investigation of Intercept Pharmaceuticals, Inc. According to a report issued by Bloomberg, Intercept Pharmaceuticals, Inc. dropped to its lowest price since 2013 today after analysts cut their price targets for the shares. This occurred following reports of additional patient deaths and a warning by the U.S Food and Drug Administration. On Thursday, the FDA said it has identified 19 deaths of people on the Intercept’s drug, Ocaliva and that the drug may also be associated with liver in injury in some patients with mild diseases who are receiving the correct dose. The company’s stock fell as much as 17 percent on Friday, after dropping 25 percent the day before. Analysts are now calling into question the credibility of Intercept’s management after FDA’s safety announcement raised concerns beyond what was mentioned in a letter the Company sent to doctors the previous week.
Arons & Arons, LLC. announces investigation on behalf of NuVasive, Inc. Investors
September 20, 2017
The Law Firm of Arons & Arons, LLC. has initiated an investigation of NuVasive, Inc. (“NuVasive or the “Company”) (NASDAQ:NUVA) on behalf of the company’s investors for possible violations of federal securities law.
If you are an investor in NuVasive, Inc. who has suffered a loss as a result of the alleged fraud click here to provide us with your purchase/sale information.
August 04, 2017
SOUTH ORANGE, N.J.--(BUSINESS WIRE)-- The Law Firm of Arons & Arons, LLC has initiated an investigation of Electronics For Imaging, Inc. (“Electronics Imaging” or the “Company”) (Nasdaq: EFII) on behalf of the Company’s shareholders regarding potential violations of the federal securities laws.